Edition:
United Kingdom

Genocea Biosciences Inc (GNCA.OQ)

GNCA.OQ on NASDAQ Stock Exchange Global Market

0.81USD
23 Apr 2018
Change (% chg)

$-0.05 (-6.33%)
Prev Close
$0.87
Open
$0.86
Day's High
$0.88
Day's Low
$0.81
Volume
64,999
Avg. Vol
238,530
52-wk High
$7.28
52-wk Low
$0.79

Select another date:

Fri, Mar 9 2018

BRIEF-Genocea Biosciences Says Jonathan Poole Delivered Resignation As CFO

* GENOCEA BIOSCIENCES - ‍ON MARCH 6, JONATHAN POOLE DELIVERED RESIGNATION AS CFO EFFECTIVE MARCH 23, 2018​

BRIEF-Genocea Qtrly Loss Per Share $0.37

* GENOCEA REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

BRIEF-Genocea Biosciences Entered Into Agreement With Oncovir For Manufacture & Supply Of Hiltonol

* GENOCEA BIOSCIENCES SAYS ‍ON JAN 26, CO ENTERED INTO AGREEMENT WITH ONCOVIR FOR MANUFACTURE & SUPPLY OF HILTONOL(REG) (POLY-ICLC)​ - SEC FILING Source text: (http://bit.ly/2npDhjw) Further company coverage:

BRIEF-Bvf Partners Reports A 8.9 Pct Passive Stake In Genocea Biosciences As Of Jan 17

* BVF PARTNERS L.P. REPORTS A 8.9 PERCENT PASSIVE STAKE IN GENOCEA BIOSCIENCES INC AS OF JAN 17 - SEC FILING Source text for Eikon: (http://bit.ly/2BDcCno) Further company coverage:

BRIEF-New Enterprise Associates 16 Reports A 39.7 Pct Stake In Genocea Biosciences As Of Jan 17

* NEW ENTERPRISE ASSOCIATES 16, L.P. REPORTS A 39.7 PERCENT STAKE IN GENOCEA BIOSCIENCES INC AS OF JAN 17 - SEC FILING Source text: (http://bit.ly/2Gm4D1B) Further company coverage:

BRIEF-Genocea Biosciences, Inc. Announces Pricing Of $55 Mln Concurrent Public Offerings

* GENOCEA BIOSCIENCES, INC. ANNOUNCES PRICING OF $55 MILLION CONCURRENT PUBLIC OFFERINGS

BRIEF-Genocea Biosciences Announces Proposed Concurrent Public Offerings Of Common Stock

* GENOCEA BIOSCIENCES, INC. ANNOUNCES PROPOSED CONCURRENT PUBLIC OFFERINGS OF COMMON STOCK AND CLASS A WARRANTS AND SERIES A CONVERTIBLE PREFERRED STOCK AND CLASS A WARRANTS

BRIEF-Genocea Biosciences inc qtrly ‍loss per share $0.59​

* Genocea biosciences - ‍expects existing cash and cash equivalents sufficient to support operating expenses and capital expenditure into middle of 2018​

Select another date: